Zika virus vaccine - Sanofi Pasteur

Drug Profile

Zika virus vaccine - Sanofi Pasteur

Alternative Names: Zika virus purified inactivated vaccine - Sanofi Pasteur; ZIKV vaccine - Sanofi Pasteur; ZPIV - Sanofi Pasteur

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Sanofi Pasteur
  • Developer National Institute of Allergy and Infectious Diseases; Sanofi Pasteur; Walter Reed Army Institute of Research
  • Class Viral vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Zika virus infection

Most Recent Events

  • 01 Nov 2016 Phase-I clinical trials in Zika virus infection (Prevention) in USA (IM) (NCT02963909)
  • 01 Oct 2016 Beth Israel Deaconess Medical Center initiates enrolment in the Z001 phase I trial for Zika virus infection (Prevention) in USA (NCT02937233)
  • 01 Oct 2016 National Institute of Allergy and Infectious Diseases initiates a phase I trial for Zika virus infection (Prevention) in USA (IM) (NCT02952833)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top